366 research outputs found
A diffĂșz nagy B-sejtes lymphoma modern szemlĂ©lete Ă©s kezelĂ©se | Recent advances in the understanding and treatment of diffuse large B-cell lymphoma
Absztrakt
A diffĂșz nagy B-sejtes lymphoma a leggyakoribb a non-Hodgkin-lymphomĂĄk között. A
ciklofoszfamid-vincristin-adriablastin-prednisolon kemoterĂĄpiĂĄval a betegeknek
mĂĄr közel 50%-a meggyĂłgyĂthatĂł volt, majd a rituximab hozzĂĄadĂĄsĂĄval a gyĂłgyulĂĄsi
arĂĄny mĂĄr 60% fölĂ© emelkedett. Ez a javulĂĄs jelentĆs, de tovĂĄbbi növekedĂ©st
kellene elérni a betegek gyógyulåsi arånyåban. Az utóbbi években elvégzett
genetikai vizsgĂĄlatok szĂĄmos Ășj, a patogenezisben is szerepet jĂĄtszĂł Ă©s terĂĄpiĂĄs
cĂ©lpontkĂ©nt is szolgĂĄlĂł mutĂĄciĂłt azonosĂtottak a betegsĂ©gben. A diagnosztika ma
mĂĄr rutinszerƱen alkalmazza a 18-fluoro-deoxi-glĂŒkĂłz-pozitronemissziĂłs
komputertomogråfiås vizsgålatokat a Lugano klasszifikåciós rendszer részeként.
Ezen adatok alapjĂĄn egyre pontosabban meghatĂĄrozhatĂł a betegek prognĂłzisa, Ă©s
kivĂĄlaszthatĂłk azok a betegek, akik valamelyik Ășj, szelektĂven hatĂł gyĂłgyszerre
esetleg reagĂĄlhatnak. Mindezeknek a kĂ©rdĂ©seknek a megvĂĄlaszolĂĄsa, az Ășjabb
kezelĂ©sek bevezetĂ©se vĂĄrhatĂłan a közeli jövĆben tovĂĄbb fogja javĂtani a betegek
tĂșlĂ©lĂ©si esĂ©lyeit. Az összefoglalĂł közlemĂ©ny ĂĄttekintĂ©st ad a közelmĂșlt
ĂșjdonsĂĄgairĂłl, kiemeli a ma hasznĂĄlatos Ă©s javasolt kezelĂ©seket, tovĂĄbbĂĄ
ĂĄttekintĂ©st ad a jelenleg kiprĂłbĂĄlĂĄs alatt ĂĄllĂł Ă©s bevezetendĆ kezelĂ©sekrĆl is.
Orv. Hetil., 2016, 157(31), 1232â1241.
|
Abstract
Diffuse large B-cell lymphoma is the most common type of non-Hodgkinâs lymphoma.
Using the conventional cyclophosphamide adriablastin vincristin prednisolon
polychemotherapy about 50% of the patients were cured. The addition of rituximab
to the regimen increased the cure rate to 60%. This is a major improvement,
however, further advance is still needed to increase the cure rate. The
extensive genetic testing performed recently revealed several important
pathognomic mutations as potential targets in this disease. Routine diagnosis of
patients now includes the use of 18Fluor-deoxy-glucose positron
emission computer tomography, according to the recent Lugano classification
system. With all these data we can better predict the prognosis of patients, and
we can select candidates for novel targeted therapies as well. Answering these
questions, and utilizing novel therapies possibly will further increase the cure
rate in the near future. This paper summarizes current diagnostic and
therapeutic approaches and describes recent understanding in the mutations and
pathognomic changes resulting in the disease. The authors also summarize the
data available on experimental therapies possibly entering clinical pratice in
the forthcoming years. Orv. Hetil., 2016, 157(31),
1232â1241
Employment status and health related quality of life among Hodgkin-lymphoma survivors'- results based on data from a major treatment center in Hungary
L
Pulmonalis eltérések Hodgkin-lymphomåban
Absztrakt
A Hodgkin-lymphoma kezelése a hematológia sikertörténetei közé tartozik. A
korszerƱ kombinĂĄlt kemo- Ă©s radioterĂĄpiĂĄnak köszönhetĆen a betegek jelentĆs
rĂ©sze tĂșlĂ©l, Ăgy elĆtĂ©rbe kerĂŒlnek a kezelĂ©sek mellĂ©khatĂĄsai, amelyek a betegek
kĂ©sĆbbi Ă©letminĆsĂ©gĂ©t Ă©s Ă©lettartamĂĄt befolyĂĄsolhatjĂĄk. A szerzĆk a
Hodgkin-lymphoma tĂŒdĆben elĆfordulĂł megjelenĂ©si formĂĄit Ă©s a kezelĂ©s
következtĂ©ben kialakulĂł pulmonalis eltĂ©rĂ©seket, szövĆdmĂ©nyeket elemzik â sajĂĄt
eseteik pĂ©ldĂĄjĂĄn. A Hodgkin-lymphoma tĂŒdĆĂ©rintettsĂ©ge gyakrabban mĂĄsodlagos,
primer pulmonalis Ă©rintettsĂ©g igen ritkĂĄn fordul elĆ. A szerzĆk sajĂĄt betegeik
vizsgĂĄlata sorĂĄn tĂŒdĆĂ©rintettsĂ©get összesen az esetek 8â12%-ĂĄban Ă©szleltek. A
kezelĂ©s rövid Ă©s hosszĂș tĂĄvĂș pulmonalis mellĂ©khatĂĄsait egyrĂ©szt az
immunszuppressziĂłval összefĂŒggĂ©sben lĂ©vĆ infekciĂłk, mĂĄsrĂ©szt a jelenleg elsĆ
vonalbeli standard kezelĂ©s rĂ©szĂ©t kĂ©pezĆ bleomycin, illetve a mellkasi
irradiĂĄciĂł okozta pneumonitis Ă©s fibrosis jelentik. A Hodgkin-lymphoma
pulmonalis megjelenése egyrészt diagnosztikai és differenciåldiagnosztikai
nehĂ©zsĂ©geket jelenthet, stĂĄdiumot Ă©s ennek következtĂ©ben kezelĂ©st mĂłdosĂthat,
mĂĄsrĂ©szt a kialakulĂł mellĂ©khatĂĄsok a kĂ©sĆbbi Ă©lettartamot Ă©s Ă©letminĆsĂ©get
jelentĆsen meghatĂĄrozzĂĄk, Ăgy felismerĂ©sĂŒk döntĆ fontossĂĄgĂș. Orv. Hetil., 2016,
157(5), 163â173
A myeloma multiplex megközelĂtĂ©se MagyarorszĂĄgon 2016-ban
Absztrakt
A myeloma multiplex kezelĂ©se az elmĂșlt Ă©vtizedben ĂłriĂĄsit vĂĄltozott. Mind a
kemoterĂĄpiĂĄs protokollok, mind a szupportĂv kezelĂ©s nagy fejlĆdĂ©sen ment ĂĄt,
amióta a legutóbbi magyar ajånlås megjelent. A betegek egyre nagyobb része ér el
tartĂłs vĂĄlaszt, Ă©s mind többĂŒk szĂĄmĂĄra van talĂĄn esĂ©ly a gyĂłgyulĂĄsra is. Az
összefoglalĂł cĂ©lja, hogy az utĂłbbi Ă©vek eredmĂ©nyeit is beĂ©pĂtve, az Ă©rvĂ©nyes
nemzetközi ajĂĄnlĂĄsokat a magyar viszonyok sajĂĄtossĂĄgaihoz adaptĂĄlva segĂtse a
betegek leghatékonyabb kezelését. Orv. Hetil., 2016, 157(4),
123â137
ImmunolĂłgiai vĂĄltozĂĄsok diffĂșz nagy B-sejtes lymphomĂĄban Rituximab-CHOP kezelĂ©st követĆen: sajĂĄt adatok elemzĂ©se Ă©s irodalmi ĂĄttekintĂ©s
Hypokalemic myopathy in a patient with gluten-sensitive enteropathy and dermatitis herpetiformis Duhring: a case report
Changing Patterns in the Clinical Pathological Features of Hodgkin Lymphoma: A Report from Debrecen, Hungary
Introduction. Hodgkin lymphoma shows a well-known geographic pattern, but temporal changes have been found recently as well.
Patients and Methods. 439 Hodgkin lymphoma patients' clinicopathological and treatment data were processed in calendar periods of approximately ten years. The patients were treated at our department from 1980 until the end of 2008.
Results. The first period (1980â89) contained 177 patients, the second (1990â99) 147, and the third (2000â08) 115 Hodgkin lymphoma patients. The mean age of the patients was 40.1, 35.9, and 36.8 years in order. The male/female ratio: 1.42, 1.45, 1.05 in order. Contrary-wise a unimodal age group pattern could have been seen with an incidence peak between 30 and 39 in the past decades. The incidence of classical mixed cellularity histological subtype is decreasing (43.7%, 58.23%, 42.6%, P = 0.0098 (it is only significant in the second period)); classical nodular sclerosis shows an increasing tendency (25%, 27.32%, 34.78%, P = 0.1734). The first incidence peak is predominantly created by classical nodular sclerosis, meanwhile the second peak by classical mixed cellularity. The number of early-stage patients (59.12%) is beyond the advanced stage (40%) in the last decade. Meanwhile, the number of second-stage patients was increasing (25.8%, 26.35%, 49.56%ââP < 0.0001) and of patients in third stage was decreasing (53.4 %, 50.67%, 20%ââP < 0.0001). The 5- and 10-year overall survival data were progressing: 59.7 %, 77.4 %, and 90.5 % and 44.1 %, 70.6 % and 90.5 % (expected survival) in the last decade.
Conclusions. Changes can be explained by the altered nature of Hodgkin lymphoma, the changes in socioeconomic status and the development of diagnostic and therapy methods
Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary
Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01/01/2016 and 31/12/2020. We assessed the progression-free and overall survival, the prognostic role of PET/CT performed before transplantation and effect of brentuximab vedotin (BV) treatment on survival outcomes. The median follow-up time from AHSCT was 39 (1-76) months. The 5-year OS comparing PET- and PET + patients was 90% v. 74% (p = 0.039), and 5-year PFS was 74% v. 40% (p = 0.001). There was no difference in either OS or PFS compared to those who did not receive BV before AHSCT. We compared BV treatments based on their indication (BV only after AHSCT as maintenance therapy, BV before and after AHSCT as maintenance treatment, BV only before AHSCT, no BV treatment). There was statistically significant difference in the 5-year PFS based on the inication of BV therapy. Recovery rates of our R/R HL patient population, who underwent AHSCT, improved significantly. Our positive results can be attributed to the PET/CT directed, response-adapted treatment approach, and the widespread use of BV
- âŠ